What Regumen Treats: Main Uses and Benefits

Regumen is a Combined Oral Contraceptive (COC) used in situations involving certain distressing symptoms related to reproductive health. The central clinical use of Regumen is commonly used to help with managing unwanted fertility for sexually active women of reproductive age. This class of medication can be used to address other health conditions, particularly menstrual-related disorders.

The medication is applied in addressing conditions involving episodic or fluctuating manifestations such as menstrual cycle irregularity, excessive uterine bleeding (menorrhagia), and menstrual cramps (dysmenorrhea). It is applied in addressing symptom clusters that create noticeable physiological strain and interfere with daily functioning.

This focus on both fertility management and symptom management may provide support that assists with maintaining functional stability in the context of reproductive planning, while contributing to improved comfort during periods of heightened symptoms.

“Regumen is commonly used to help with managing symptoms related to physical discomfort during the menstrual phase, while assisting with fertility management.”

---

Quick Fact: Supportive Management for Physical Discomfort

Quick Fact: Supportive Management for Physical Discomfort Regumen is commonly used to help with managing these conditions, supporting a more predictable cycle and assisting with the overall symptom load during periods.

Regulatory References

1. NIH National Library of Medicine StatPearls overview

Eligibility and Contraindications for Regumen (Metoclopramide)

Official regulatory guidelines strictly define the patient populations who can and cannot use Regumen to manage risks, particularly the risk of irreversible neurological disorders like tardive dyskinesia.

Populations Who Must Not Use Regumen (Contraindications)

Use of Regumen is absolutely prohibited in individuals with:

• A known hypersensitivity to metoclopramide or its ingredients.
• Any condition where stimulating gut movement is dangerous, such as gastrointestinal hemorrhage, obstruction, or perforation.
• A history of tardive dyskinesia or extrapyramidal symptoms induced by neuroleptics.
• Certain neurological or hormonal conditions, including epilepsy or a known or suspected pheochromocytoma.
• Concomitant use with levodopa or dopaminergic agonists.

Age-Related and Conditional Eligibility

Age/Condition	Eligibility Status (Regulatory)
Infants/Neonates (<1 yr)	Contraindicated due to heightened risk of neurological and blood disorders.
Pediatric Patients (1-18 yrs)	Not recommended (US) or highly restricted (EU) to specific short-term indications.
Older Adults (Geriatrics)	Requires special consideration and often a reduced initial dose due to increased neurological risk.
Renal/Hepatic Impairment	Conditional use; requires mandatory dose reduction in cases of moderate to severe impairment.
Pregnancy/Lactation	Use not recommended during lactation; use in pregnancy is generally reserved for clear necessity.

Treatment duration for all patients is severely limited (e.g., typically not more than 12 weeks in the US) to mitigate the long-term risk of movement disorders.

Regumen’s official interaction profile is primarily defined by pharmacokinetic changes that alter the plasma concentrations of its hormonal components, Ethinyl Estradiol and Norethisterone (the active metabolite of Lynestrenol).

Contraindicated Combinations

Co-administration with certain Hepatitis C combination regimens is formally prohibited due to the documented risk of elevated liver enzymes (ALT). This restriction applies to regimens containing Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir, as well as combinations containing Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir/Voxilaprevir.

Exposure-Altering Interactions

Medicinal products that induce hepatic enzymes, particularly CYP3A4, increase the clearance of Regumen's hormones, resulting in reduced systemic exposure. This is officially classified as a risk for loss of expected efficacy. Documented inducers include certain anticonvulsants (e.g., Carbamazepine, Phenytoin) and antibiotics (e.g., Rifampicin). Conversely, drugs that inhibit CYP enzymes, such as azole antifungals, can increase hormonal exposure. Regumen may also increase the plasma concentration of co-administered drugs, including Tizanidine and Theophylline.

Timing and Herbal Restrictions

The administration of Regumen and the bile acid sequestrant Colesevelam must be separated by at least four hours. The herbal product St. John's Wort (Hypericum perforatum) is restricted for concomitant use as it is documented to reduce the plasma concentration of the hormonal components.

Regumen's mechanism of action centers on its role as a selective progesterone receptor modulator (SPRM). The drug preferentially accumulates in reproductive tissues, particularly the uterus, ovaries, and hypothalamus.

Its primary biological target is the progesterone receptor (PR), where it acts as a mixed agonist/antagonist, with the specific interaction type being tissue-dependent. In the pituitary gland, the drug inhibits the release of luteinizing hormone (LH) via PR antagonism in the hypothalamus, which suppresses the downstream cascade of follicular rupture. In the endometrium and myometrium, its action modulates gene transcription mediated by the progesterone receptor, leading to inhibition of cell proliferation and induction of apoptosis within the target tissue. System-level physiological consequences include a transient disruption of the normal hypothalamic-pituitary-gonadal axis, specifically leading to anovulation and functional changes in the uterine lining.

Regumen is a fixed-dose combined hormonal contraceptive prescribed for oral administration. The usage regimen is based on a 28-day cycle of continuous administration. The established schedule involves taking one tablet daily at approximately the same time each day, which is a factor for maintaining consistent systemic levels.

The 28-day regimen is structurally divided: it consists of 21 consecutive days of taking the hormonally active tablet, followed immediately by 7 consecutive days of taking an inert (hormone-free) tablet. This sequence is intended to structure the overall use protocol. The medicine may be taken with or without food, and the numerical or directional order printed on the blister packaging is followed to adhere to the proper sequence of active and inactive pills.

Administration is designed for long-term use in women of reproductive potential. Initiation protocols generally involve either a Day 1 Start (beginning on the first day of the menstrual period) or a Sunday Start. It is procedurally essential that the interval between any two active doses does not exceed 24 hours. Specific instructions exist for managing missed doses, which vary depending on the week of the cycle and the number of tablets missed. When transitioning to a new pack, administration continues without a prolonged tablet-free interval beyond the 7 days defined by the inert tablets.

Research Evidence / Overview of Studies for Regumen

Evidence for Use in Pregnancy Prevention (Contraception)

Research related to this medicine was studied using Randomized Controlled Trials (RCTs) and large prospective observational cohort studies. These studies have primarily evaluated contraceptive efficacy, which is measured by calculating the likelihood of unintended pregnancy using metrics like the Pearl Index. Studies consistently report the observed measurement of pregnancy rates in the populations studied when the medicine was used with perfect consistency and correctness. However, the research also highlights that in typical real-world use—which factors in human error like missed doses—measurements of the rate of unintended pregnancy were different under conditions of typical use.

Evidence for Use in Managing Menstrual Symptoms

For non-contraceptive uses, the research base explores the combined hormonal component in study contexts related to excessive uterine bleeding (menorrhagia) and menstrual cramps (dysmenorrhea). Trials focus on outcomes like objective measurements of menstrual blood loss (MBL) and changes in pain intensity. For MBL, findings describe the measurements observed during the study period compared to placebo over typical short-term study periods of three to six months. For cramps, research describes patterns of change in pain scores compared to placebo, with changes observed during the four to six months study period. Comparative evidence against all other available hormonal treatments remains limited in scope.

Study Limitations and Areas of Uncertainty

While the overall evidence landscape includes a large volume of data for contraception, certain limitations exist. Long-term effects are not fully established for all non-contraceptive uses, and data for certain groups of patients with underlying complex health conditions remains insufficient. The results apply only to the populations studied, and comparative evidence is lacking for many specific formulations, meaning that findings often describe the class of combined contraceptives rather than providing granular detail on the specific Lynestrenol/Ethinyl Estradiol combination against all alternatives. Research provides context but not individual predictions, emphasizing that findings describe group patterns, not personal outcomes.

Key Studies & References

1. FDA Approved Prescribing Information for Norethindrone and Ethinyl Estradiol Tablets (Typical COC Label)
2. ACOG Practice Bulletin No. 110: Noncontraceptive Uses of Hormonal Contraceptives

Common questions about Regumen (FAQ)

---

Q: Can I take Regumen with alcohol?

Regulatory documents advise that alcohol consumption be avoided during treatment with Regumen. Official product information contains a specific warning regarding the combination due to potential interactions.

---

Q: What should I do if I miss a dose?

Regulatory guidance often suggests taking the missed dose as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the regulatory instruction is generally to skip the missed dose. Patients are cautioned not to take a double dose to make up for a forgotten dose.

---

Q: Is it safe to use Regumen if I am pregnant?

Regulatory documents typically indicate that use during pregnancy is not recommended. This position is taken due to insufficient data or studies that confirm its safety for use during this specific period.

---

Q: Does Regumen make you sleepy or dizzy?

Product information notes that somnolence (sleepiness) and dizziness are listed as commonly reported side effects of Regumen. These are noted in the official safety profile of the medication.

---

Q: Can children 2 years old use Regumen?

According to the approved regulatory documentation, Regumen is approved for use in patients aged 12 years and older. Use in pediatric patients under this age is generally not supported by the current regulatory approval.

How to Store and Dispose of Regumen (Ethinyl Estradiol, Lynestrenol)

Regumen must be stored under specific environmental conditions as documented in regulatory labeling to maintain its stability and effectiveness.

Official Storage Requirements

Condition	Requirement
Temperature	Store at a controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Keep the tablets away from excessive heat and moisture.
Packaging	The medication must remain in its original blister pack.
Child Safety	Store Regumen out of the sight and reach of children.

Disposal

Discard unused or expired Regumen tablets according to local regulations or by utilizing a pharmaceutical drug take-back program. Regulatory guidance often advises against disposing of medication by flushing it down the toilet or throwing it into household wastewater.